Boehringer Ingelheim and Epizyme announced a partnership on Thursday to develop oncology treatments.The partnership entails developing, researching and commercializing small molecule inhibitors directed for two epigenetics targets as potential cancer therapies.
The post Boehringer Ingelheim Partners with Epizyme appeared first on Investing News Network.
Original Article: Boehringer Ingelheim Partners with Epizyme